AI Article Synopsis
Article Abstract
Objectives: To investigate the immune status of children with very severe aplastic anemia (VSAA), and evaluate the frequencies of CD20 B cells and Regulatory T cells (Tregs) as potential markers for evaluating the therapeutic efficacy and prognosis.
Methods: We systematically analyzed CD20 B cells and Tregs using Flow Cytometry in 36 children with VSAA (14 newly diagnosed cases and 22 cases in remission after therapy with HDIVIG + r-ATG + CSA).
Results: In newly diagnosed VSAA patients, the percentage of CD20 B cells was higher than that in healthy children (P < .01), whereas the percentage of Tregs was lower than that in healthy children (P < .001). After treatment with HDIVIG + r-ATG + CSA, the percentage of CD20 B cells in peripheral blood was decreased obviously, and the percentage of Tregs was significantly increased.
Conclusion: There is a moderate negative correlation between the percentage of Tregs and CD20 B cells in our study. Our results shed light on the roles of Tregs and CD20 B cells as therapeutic efficacy and prognostic markers of pediatric VSAA. Moreover, the mechanism underlying the decrease of blood Tregs and increase of CD20 B cells in pediatric VSAA patients have been discussed, indicating that Tregs may suppress B cell responses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10245332.2018.1498566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progressive anterior segment involvement of an infant with corneoscleral juvenile xanthogranuloma refractory to topical steroids.
Am J Ophthalmol Case Rep
December 2024
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Purpose: To report a case of corneoscleral juvenile xanthogranuloma (JXG) with progressive anterior segment involvement refractory to topical steroids.
Observations: A 4-month-old male was referred for a new-onset subconjunctival lesion in the right eye. He was found to have a thickened, yellow corneoscleral lesion and hyphema, presumed to be ocular JXG.
B cells recruitment promotes M2 macrophage polarization to inhibit inflammation during wound healing.
Clin Exp Immunol
January 2025
Department of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Introduction: Wound healing causes heavy economic burdens for families and society, becoming a critical issue in the global healthcare system. While the role of immune cells in the wound healing process is well-established, the involvement of B cells remains poorly understood. This study aims to elucidate the essentiality of B cells in wound repair.
View Article and Find Full Text PDFThe emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.
Clin Adv Hematol Oncol
December 2024
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.
The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease. Herein, we review and discuss the standard-of-care products and indications for mosunetuzumab, epcoritamab, and glofitamab. We provide a detailed overview of the registrational clinical trials, as well as a review of ongoing trials and likely future indications.
View Article and Find Full Text PDFAlterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
March 2025
Yale School of Medicine Department of Neurology, New Haven, CT.
Background And Objectives: Gut microbial symbionts have been shown to influence the development of autoimmunity in multiple sclerosis (MS). Emerging research points to an important relationship between the microbial-IgA interface and MS pathophysiology. IgA-secreting B cells are observed in the MS brain, and shifts in gut bacteria-IgA binding have been described in some patients with MS.
View Article and Find Full Text PDFOpportunities and limitations of B cell depletion approaches in SLE.
Nat Rev Rheumatol
January 2025
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
B cell depletion with rituximab, a chimeric monoclonal antibody that selectively targets B cells by binding CD20, has been used off label in severe and resistant systemic lupus erythematosus (SLE) for over two decades. Several biological mechanisms limit the efficacy of rituximab, including immunological reactions towards the chimeric molecule, increased numbers of residual B cells, including plasmablasts and plasma cells, and a post-treatment surge in B cell-activating factor (BAFF) levels. Consequently, rituximab induces remission in only a proportion of patients, and safety issues limit its use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!